 SAN DIEGO, June 16, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Garlan Adams to the newly created role of general counsel. Ms. Adams brings to Crinetics more than two decades of experience managing legal and compliance matters associated with the development and commercialization of innovative pharmaceutical and biotechnology products. 